

Resource Summary Report

Generated by [NIF](#) on Sep 5, 2026

CHO

RRID:CVCL_0213

Type: Cell Line

Proper Citation

CLS Cat# 603479, RRID:CVCL_0213

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0213

Proper Citation: CLS Cat# 603479, RRID:CVCL_0213

Description: Cell line CHO is a Spontaneously immortalized cell line with a species of origin Cricetulus griseus (Chinese hamster)

Sex: Female

Defining Citation: [PMID:4120885](#), [PMID:13598821](#), [PMID:34050613](#)

Category: Spontaneously immortalized cell line

Organism: Cricetulus griseus (Chinese hamster)

Name: CHO

Synonyms: Chinese Hamster Ovary, CHO-ori

Cross References: BTO:BTO_0000246, CLO:CLO_0002421, EFO:EFO_0022760, MCCL:MCC:0000102, CLDB:cl721, CLDB:cl722, CLDB:cl724, CCRID:1101HAM-PUMC000116, CCRID:5301HAM-KCB83004YJ, ChEMBL-Cells:ChEMBL3308072, ChEMBL-Targets:ChEMBL613853, CLS:603479, ECACC:85050302, IBRC:C10028, ICLC:ATL95003, KCB:KCB 82012YJ, KCB:KCB 83004YJ, Lonza:755, MeSH:D016466, NCBI_Iran:C111, PubChem_Cell_line:CVCL_0213, Wikidata:Q56646

ID: CVCL_0213

Vendor: CLS

Catalog Number: 603479

Record Creation Time: 20220624T070405+0000

Record Last Update: 20260905T182935+0000

Ratings and Alerts

No rating or validation information has been found for CHO.

No alerts have been found for CHO.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 733 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Deiktakis M, et al. (2026) NGF promotes, in an autocrine-paracrine manner, metabolic and anti-inflammatory pathways in human and mouse adipocytes. *The Journal of clinical endocrinology and metabolism*, 111(7), e1892.

Ravazza D, et al. (2026) Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(38), e20265.

Pfister SK, et al. (2026) Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies. *Molecular cancer therapeutics*, 25(2), 310.

Lee HS, et al. (2026) Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP+ Model of Parkinson's Disease. *Journal of neurochemistry*, 170(2), e70363.

El Sahili A, et al. (2026) Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. *Molecular cancer therapeutics*.

Wu S, et al. (2026) MKOP002, a novel bifunctional μ - κ -opioid decapeptide with G protein-biased μ -opioid agonism, exhibits antinociceptive and antipruritic activities. *Biochemical pharmacology*, 246, 117755.

Chen D, et al. (2025) Dnajc5b contributes to male fertility by maintaining the mitochondrial functions and autophagic homeostasis during spermiogenesis. *Cellular and molecular life sciences : CMLS*, 82(1), 69.

Chen B, et al. (2025) Upregulation of hepatic flavin-containing monooxygenase 3 by increased corticosterone via glucocorticoid receptor contributes to gestational diabetes mellitus. *Drug metabolism and disposition: the biological fate of chemicals*, 53(9), 100133.

Gregory KS, et al. (2025) Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat,

quinaprilat and perindoprilat. The FEBS journal.

Li C, et al. (2025) NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e16607.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. *Journal for immunotherapy of cancer*, 13(5).

Dasgupta U, et al. (2025) Cu₃N-Fe nanocube-based electrochemical sensing of cancer metabolites with minute-scale response time. *Materials horizons*.

Zhang S, et al. (2025) Elucidation of the zinc binding site in KCNQ channels. *British journal of pharmacology*.

Asano S, et al. (2025) Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and G α i proteins, and to its functions in breast cancer cells. *British journal of pharmacology*, 182(15), 3612.

Bosch R, et al. (2024) Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. *British journal of pharmacology*, 181(12), 1874.

Mineva ND, et al. (2024) A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. *Pharmaceutics*, 16(4).

Mihlan M, et al. (2024) Neutrophil trapping and necrocytosis, mast cell-mediated processes for inflammatory signal relay. *Cell*, 187(19), 5316.

Kutzsche J, et al. (2024) An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain. *British journal of pharmacology*, 181(12), 1734.

Schoellerman J, et al. (2024) Characterization of tritiated JNJ-GluN2B-5 (3-[³H] 1-(azetidin-1-yl)-2-(6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-b]pyridin-1-yl)ethanone), a high affinity GluN2B radioligand with selectivity over sigma receptors. *Journal of neurochemistry*, 168(9), 2654.

Moquist PN, et al. (2024) Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation. *Bioconjugate chemistry*, 35(6), 855.